Harga Saham Johnson & Johnson (JNJ) Hari Ini

Le TAR-200 en monothérapie de Johnson & Johnson présente le taux de réponse complète le plus élevé rapporté à ce jour avec des bénéfices cliniques durables chez les patients atteints de certains types de cancer de la vessie

3 Industry Behemoths Are Rewarding Investors With Dividend Bumps

Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer

These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?